Avulux is proud to announce formal partnerships with Opti-Port, the eye care industry’s only alliance of growth-oriented, multi-office eye care practices, and with PERC, a collective purchasing organization committed to helping optometric practices boost profitability.
All Opti-Port and PERC member practices will have access to Avulux Migraine & Light Sensitivity Lenses, the only clinically proven lenses that precisely filter light to help people living with migraine.
Founded in 2001, Opti-Port is a national alliance of leading multi-office eye care providers that leverages the combined strength of its member companies to provide revenue enhancing, cost saving, and market expanding opportunities. Similarly, PERC offers access to a vibrant community of eyecare providers, educational programs, and study groups, empowering practices to thrive in every aspect of their business. Working together, the Opti-Port and PERC organizations enable their members with much stronger advantages than doing business on their own.
Avulux, Opti-Port and PERC collaborated on a joint commercial pilot from May through July of 2024, which was considered an overwhelming success by all three organizations. A small number of prominent Opti-Port and PERC practices collectively dispensed Avulux to hundreds of migraine patients and collected their feedback. 93% of these patients indicated that Avulux lenses decreased their sensitivity to light. Additionally, 87% of these patients said that wearing Avulux lenses allowed them to engage more fully in daily activities like work, hobbies and time with family and friends.
“Opti-Port and PERC members were some of the earliest adopters of Avulux technology, and rank among their highest-selling locations,” says Jason Lake, General Manager of PERC/Opti-Port. “We have seen firsthand the impact that Avulux can have on practices and patients, and we are proud to ensure that all Opti-Port and PERC members have access to this innovation.”
Avulux lenses incorporate a multi-band precision optical filter that works by filtering up to 97% of harmful blue, amber, red light while allowing in soothing green light. Additionally, the Avulux lens is the only lens that has been clinically proven for people living with migraine and light sensitivity. In a 2020 double blind, randomized, placebo-controlled study conducted by an independent clinical research organization, the Avulux lens achieved both clinical and statistical significance when compared to a clear placebo lens.
“Opti-Port and PERC are known industry-wide as organizations that are committed to strengthening their member practices – and the industry as a whole – through emerging technologies that have a demonstrable impact on practices and patients,” says Brant Southwell, Avulux Chief Commercial Officer. “Jason, Jamie and the entire team have been incredible partners from our inception, and we couldn’t be more excited to grow together for years to come.”